







政务微信

政务微博

头条发布

IVESTMER

GUIDE

地址: 甘肃省兰州市城关区雁南路 1258 号

Address: #1258 Yan Nan Road, Chengguan District, Lanzhou City, Gansu Province, China.

电话 /TEL: 0931-8230822 邮箱 /E-mail: lzgxzsj@163.com

网址 /Website: http://lzhtp.lanzhou.gov.cn

联系单位: 兰州高新区招商局 联系人: 姚文静 15117218386

contacts: Investment Promotion Bureau of Lanzhou National High-tech Industrial

Development Zone Management Committee



兰州国家自主创新示范区管理委员会 兰州国家高新技术产业开发区管理委员会

Lanzhou Self-dependent Innovation Demonstration Area Management Committee Administrative Committee of Lanzhou Hi-tech Industrial Development Zone

Innovation Demonstration Area







____ 02

	□基本情况	01
录	Basic information	_ 01
	□企业聚集	02
//)	Enterprise assembling	- 0_
	03 科技资源 Science and technology resources	
	04 创新资源 Innovation r esources	
	05 孵化能力 Hatchability	
	06 人才优势 Talent advantage	
	07 交通优势 Transportation advantages	
	□园区规划	_ 08
	industrial zone planning	
	09 产业布局 Industrial Distribution	
	10 产业导向 Industry orientation	
	□优惠政策	_ 15
	Preferential Policy	
	15 招商引资政策 Preferential policies for attracting investment	
	20 加快生物医药产业发展的若干措施 Some measures to accelerate the development of bio-pharmaceutical industry	of
	□投资要素	- 31



兰州高新区是国务院 1991 年批准设立的全国首批 27 个国家级高新区之一,现空间布局"一区五园"(雁滩园区、定连园区、七里河园区、九州园区、和平园区),规划控制面积为 182.77 平方公里。经过多年发展,区内创新创业资源逐步集聚。



Lazhou National Hi-tech Industrial Development Zone is one of the first batch of 27national high-tech zones approved by the State Council in 1991. Now its spatial arrangement is "one zone and five parks" (Yantan Park, Dinglian Park, Qilihe Park, Jiuzhou Park and Heping Park) and plannig control area is 183.77km2... After development for many years, innovation and entrepreneurship resources in the zone are gradually gathered.

企业聚集



全区注册登记企业达到 1.25 万多户,其中高新技术企业发展 到 308 户,占全省的 30%;战略性新兴产业骨干企业发展到 27 户,占全省的 33%,上市公司发展到 25 户,占全省的三分之一。

There are more than 12,500 registered enterprises in the zone,including 308 new high-tech enterprises,accounting for 30% of that of the whole province;27 strategic key enterprises in emerging industry,accounting for 33% of that of the whole province and 25 listed companies,accounting for one third of that of the whole province.


占全省比例 The proportion that occupies whole province

高新技术企业
High-tech enterprise
战略新兴产业骨干企业

Listed company

Backbone enterprise of strategic emerging industry

上市挂牌企业



A技资源 Science and technology resources

拥有兰州大学、兰州理工大学、兰州财经大学等多 所高等院校,中国科学院兰州分院及多个研究所,兰州 大学和兰州理工大学 2 个国家级大学科技园。

There are many institutions of higher learning such as Lanzhou University ,Lanzhou University of Technology and Lanzhou University of Finance and Economics,CAS lanzhou Branch, several research institutions and two national university science parks-Science Park of Lanzhou University and Science Park of Lanzhou University of Technology.







创新资源

Innovation resources

区内拥有国家实验室 1个,国家级重点实验室 12 个,部级重点实验室 14 个,省级重点实验室 25 个,省级实验室培育基地 18 个,省级工程实验室 18 个。拥有国家级企业技术中心 7 个,省级企业技术中心 23 个。拥有国家级工程研究中心 5 个,省级工程研究中心 45 个。国家级创新平台 27 个,省级创新平台 43 个,地方创新示范区中心 1 个。获批国家产城融合示范区、国家科技服务业试点等国家级牌子 13 个,已初步成为全省科技创新和产业升级的集中示范区。

Now, there are one national laboratory, twelve national key laboratories, fourteen ministry key laboratories, twenty-five provincial key laboratories, eighteen provincial incubating bases, eighteen provincial engineering laboratories, seven national engineering research centers, twenty-three provincial engineering research centers, five national enterprise technology centers, forty-five provincial enterprise technology centers as well as twenty-seven national innovation platforms, forty-three provincial innovation platforms,and one regional innovation pilot center, besides, thirteen national title brands, such as national industry and city integration demonstration area, national scientific service pilot area and other national title brands.



_孵化能力 Hatchability

拥有国家级孵化器 4 个、国家级众创空间 10 个,孵化器面积达到 95 万平方米。

There are four national incubators and ten national creative spaces with the incubator area reaching to 950,000m2.





人才优势 Talent advantage

柔性引进院士和专家 23 人,新引进各类实用 人才 1115 人;万人发明专利拥有量达到 45 件, 万人拥有本科学历以上人数达到 3320 人,万人 R&D 人员数达到 125 人。

There are 23 Academicians and experts by flexible introduction in the zone, there are 1115 new different practical talents brought in recently; the quantity of invention patent held by ten thousand people counting reaches 45 pieces ,the quantity of regular college course or over it held by ten thousand people counting reaches 3320 pieces , besides, the quantity of R&D personnel held by ten thousand people counting reaches 125 pieces.





- **交通优势** Transportation advantages

青兰高速、南绕城、北绕城高速公路、 快速通道穿城而过,312国道横贯全境,

Qing Lan Expressway, South Ring Expressway and North Ring Expressway and fast channel go through Lanzhou, No. 312 National Highway traverses the whole city 轨道交通 4 号线规划建设,便利的交通条件进一步凸显。

and Rail Transit Line 4 is under planning and construction, as a result, convenient traffic condition is further highlighted.

2018年2月1日,国务院正式批复同意兰州高新区建设国家自主创新示范区,这是我国西部欠发达地区第一个批准建设的国家自创区。我们将紧盯科技体制改革试验区、产业品质跃升支撑区、人才资源集聚区、东西合作发展先行区、生态文明建设引领区,加快建设高新技术产业发展的"高地"和吸引城市人口安居乐业的"洼

On Feb. 1, 2018, the State Council gives an official reply to agree construction of Self-dependent Innovation Demonstration Area in Lanzhou National Hi-tech Industrial Development Zone which is the first National Independent Innovation Demonstration Zone approved in the underdeveloped area in western China. We will pay close attention to reform experimental area of scientific and technical system, support area of industry quality zooming, nesting zone of talent resource, pilot area of east-west cooperative development and leading area of ecological civilization construction, speed up the construction of the "highland" of high and new technology industry development and the "low-lying land" for attracting urban population to live and work in peace


and contentment, build the most livable

地",打造全市乃至全省生态最宜居、功能最完善、资源最富集、生活最便捷、就业最充足的现代化科技新城,成为人人向往的地标性城区。到 2025 年,全面构建以创新驱动为主要引领和支撑的经济体系和发展模式,成为西部地区有影响力的区域科技创新中心和经济增长极。

modern science and technology city with perfect function, the richest resources, the most convenient life and the most sufficient employments in the city and even in the whole province and make it become the landmark city which everyone yearns for. By 2025, economic system and development pattern mainly led and supported by innovation driving will be comprehensively built and the Zone will become regional science and technology innovation center and economic growth pole in western China.




园区规划 规划



1991年国务院批准设立,现空间布局为"一区五园",规划控制面积 182.77平方公里,总人口 20 多万。2019年,企业总数 12500 多户,地区生产总值 277亿元,固定资产投资 188 亿元,已成为全省科技创新和产业升级的先行示范区。

In 1991, the State Council approved its establishment. Now, spatial arrangement is "one zone and five parks", planning control area is 182.77km2 and total population reaches above 0.2 million. In 2019, there were more than 12,500 enterprises, regional GDP reached RMB 27.7 billion, fixed-asset investment reached RMB 18.8 billion. The Zone became the pilot demonstration area for scientific and technological innovation and industrial upgrading in the whole province.

产业布局 Industrial Distribution



√ 雁滩园区重点发展总部经济、科技研发、软件开发、文化创意和现代服务业等产业。

Yantan Park focuses on the development of headquarters economy, technology research and development, software development, cultural creativity and modern service industries.

② 定连园区重点发展生物医药、电子信息、高端制造、科技研发、企业孵化和现代服务业等产业。

Dinglian Park focuses on the development of biomedicine, electronic information, highend manufacturing, technology reserach and development, business incubation and modern service industries.

③ 九州园区重点发展食品加工、都市加工等产业。

Jiuzhou Park foucuses on the development of food processing and urban processing industries.

4 七里河园区重点发展科技研发、烟草加工、现代服务业等产业。

Qilihe Park focuses on the developemnt of scientific and technological research and development,tobacco procesing and modern service industries.

5 和平园区重点发展新材料、现代商贸物流等产业。

Heping Park focuses on the development of new materials, modern commercial logistics and other industries.

....... 生命健康 Life health

1. 生物医药: 疫苗、血液制品、诊断试剂、药品筛选等生物制药, 抗肿瘤、乙肝、糖尿病类化学制药,现代中药及中药保健品等;

1.1. Biomedicine: Vaccine, blood product, diagnostic reagent and medicine screening and other bio-pharmaceuticals, antineoplastic, anti-hepatitis B, anti-diabetes chemical pharmaceutical, modern Chinese medicine and traditional Chinese medicine for health care;

2. 生物技术: CRO 外包服务、基因组技术、生物数据库等;

2. Biotechnology: CRO outsourcing service, genome technology, biological database, etc.;

3. <mark>健康服务</mark>: 远程医疗、精准医疗、中医药健康养老服务、智慧健康管理等。

3. Health service: Telemedicine, precision medicine, health care for the elderly by traditional Chinese medicine intelligent health management, etc.









1、<mark>高端装备:</mark>专业化、智能化、自动化、信息化设备仪器,监测设备,综合解决方案服务等;

1. High-end equipment: Professionalized, intelligentized and informationized equipment, monitoring equipment and comprehensive solution service etc.;

2、3D 打印: 增材制造研发,加快 3D 打印设备研制,培育发展 3D 打印应用服务等;

2. 3D Printing: Additive manufacturing and R&D, accelerating R&D of 3D printing equipment, cultivating and developing 3D printing application service, etc.;

3、机器人: 工业机器人系列产品,服务机器人系列产品,国内外数据服务、智能交互、运动控制、定位导航、图像识别等机器人系统核心技术。

3. 3. Robots: Industrial robot series products, service robot series products, domestic and foreign data service, intelligent interaction, motion control, positioning and navigation, image identification and other core technologies of robot system.

1、纳米材料: 纳米功能材料、生物传感技术等新材料;


1.Nanometer materials: New materials such as nanometer functional material and biosensing technique;

2、<mark>锂电池材料</mark>:镍、钴、锰等锂电池正极材料研发和生产,有色金属粉体材料、高纯金属、镍合金棒材等;

2. Lithium battery materials: R&D and production of anode material of nickel, cobalt and manganese lithium batteries, nonferrous metal powder material, high pure metal and nickel alloy bar etc.;

3、稀土材料:稀土研磨、贮氢、永磁、发光 等稀土功能材料。

3. Rare earth materials: Rare earth functional materials such as rare earth polishing, hydrogen storage, permanent magnet and shining.







1、新能源材料、自流发电技术、地岩热技术、储能技术、氢燃料电池、锂离子电池等;

1. New energy material, downgrade flow power technology, ground rock heat technology, energy storage technology, hydrogen cell, lithium ion battery, etc.;

2、能源技术开发、大气污染防治、城市污水处理、节水技术和 节能设备、资源综合利用等产业。

2. Energy technology development, air pollution control, treatment of municipal sewage, water saving technology and energy-efficient equipment, comprehensive utilization of resources, etc.



优惠政策





医疗大数据: 临床辅助决策、公众疫情监测、个性化医疗等;

Medical big data: Clinical aid decision making, public epidemic surveillance, personalized medical treatment, etc.;



工业大数据:工业物联网应用等;

Industrial big data: Industrial IoT application, etc.;



地理地质大数据: 地理信息测绘、地质灾害监测预警等;

Big data of geography and geology: Surveying and mapping of geographic information, geological hazard monitoring and forewarning, etc.;



民生大数据: 大数据精准扶贫、在线教育等;

Big data of people's livelihood: Targeted poverty alleviation of big data, online education, etc.;



智慧城市: 城市信息基础设施建设,公共数据资源,智慧政务、智慧交通、智慧公安等。

Smart city: City information infrastructure construction, common data resources, intelligent government affairs, intelligent transportation and intelligent public security.

兰州高新区建设国家自主创新示范区 招商引资优惠政策



Construction of Self-dependent Innovation Demonstration Area in Lanzhou National Hi-tech Industrial Development Zone

第一条 Article I

为进一步加大兰州、白银国家自主创新示范区(以下简称"兰州自创区")东西合作、对外开放招商引资工作力度,引进行业龙头骨干企业,补齐和延伸产业链,形成产业集群,打造特色园区,特制定本政策。

This policy is hereby formulated to further expand the west-east cooperation, opening-to-outside and investment promotion in Lanzhou and Baiyin Self-dependent Innovation Demonstration Area hereinafter referred to as "Lanzhou Self-dependent Innovation Demonstration Area"), introduce the leading backbone enterprises in the industry, make up and extend the industry chain, form a industry cluster and create a characteristic park.



第二条 Article II

本政策适用于在兰州高新 区范围内合法投资经营、纳税 的各类投资主体和独立核算的 法人企业。重点支持战略性新 兴产业、高新技术产业及兰州 自创区确定的生命健康、智能 制造、新材料、节能环保和大 数据应用等主导产业。

This policy applies to all types of investment entities that are legally invested and operated and independent accounting companies within the scope of Lanzhou National Hi Tech Industrial Development Zone. The policy supports the strategic emergency industries, hightech industries and leading industries of life health, intelligent manufacturing, new materials, energy conservation and environmental protection,

big data application determined in Lanzhou Self-dependent Innovation Demonstration Area.

第三条 Article III

对新入驻定连园区,投资 强度在 300 万元 / 亩以上的高 新技术产业项目(属于《国家 重点支持的高新技术领域目录 2017》规定的范围),经相关 程序认定,按照签定土地出 成交确认书之日起至项政按是 投产,兰州高新区财政按照 投产,兰州高新区财政按资强度,以企业缴纳土地 以企业缴纳土地 以不含代征用地)出让金为 其中项目固定资产投资额以审计 报告为准。

For the new high-tech industrial projects settled in Dinglian Park with investment intensity of more than RMB 3 million / mu (within the

scope stipulated in Catalogue of High-tech Fields Mainly Supported by the State 2017), the relevant procedures have confirmed that, from the date of signing the contract confirmation of land transfer until the project is completed and put into operation, the finance department of Lanzhou National Hi-tech Industrial Development Zone shall, in accordance with the fixed asset investment and investment intensity actually completed by the project, give reward in the proportion as below based on the transfer fee paid by the enterprise to the land (excluding the planning land). The fixed-assets investment amount of the project is subject to the auditing report.

固定资产投资额 Fixedasset investment 奖励标准 Standardfor incentives 投资强度 Investment Intensity	0.2-1 亿元 RMB 20-100 million		3-10 亿元 RMB 300- 1000 million	10-20 亿元 RMB 1-2 billion	20 亿元以上 Above RMB 2 billion
300 万元 / 亩以上 More than RMB three million/mu	10%	30%	50%	70%	90%

建设周期要求: 固定资产 投资额在10亿元以下(含) 的项目建设周期不超过 24 个 月,投资额在10亿元以上的 项目建设周期不超过36个月。 实际建设周期较以上要求每延 长2个月,奖励标准下调5个 百分点, 若延长期超过限定期 限的一半,不得享受本条优惠 政策。对于兰州自创区重点支 持的生物医药、智能制造、新 材料、节能环保和大数据应用 领域的重点项目奖励标准上调 10个百分点。对分期建设的 项目,按分期实际固定资产投 资额审核奖励。

Construction duration requirements: The construction period of projects with fixed assets investment below RMB 1 billion (including) shall not exceed 24 months, and the construction period of projects with investment above 1 billion shall not exceed 36 months. If the actual construction cycle is extended by 2 months, the incentive standard is reduced by 5%. If the extension period exceeds half of the specified period, the preferential policy of this article shall not be enjoyed. The award standards for key projects in the areas of biomedicine, intelligent manufacturing, new materials, energy conservation and environmental protection

and big data application in Lanzhou Self-dependent Innovation Demonstration Area are increased by 10%. For the projects built by phases, they shall be reviewed and rewarded according to the actual investment amount of fixed assets by phases.

第四条 Article IV

对世界 500 强、中国 500 强、民营 100 强或行业龙头企业在定连园区建立生产基地,项目符合园区规划、产业导向及投资强度等要求的,在项目建成投产后,以其缴纳土地出让金为基数,按一定比例给予奖励,最高可按 100% 奖励。

For the world's top 500, China's top 500, private 100 enterprises or industry leading enterprises establish

production bases in Dinglian Park, if those projects meet the requirements of park planning,

industry orientation and investment intensity, after the projects are completed and put into production, rewards will be granted in a certain percentage on the basis of their land-transferring fees, and the

maximum rewards can up to 100%.

第五条 Article V

对新入驻定连园区,投资强度在300万元/亩以上的生产性项目,固定资产投资达到5000万元以上的,在投产之前新增固定资产投资额(不含土地出让金)的贷款部分,经相关程序认定,给予项目企业贷款同期基准利率50%的贴息。

For the new production projects that are settled in the Dinglian Park and have an investment intensity of more than RMB 3 million/mu, and their fixed assets investment reaches RMB 50 million or above, the loans for additional investment of fixed assets (excluding land-transferring fees) before



putting into production shall be given a discount of 50% of benchmark interest rate over the same period as determined by by relevant procedures.

第六条 Article VI

对世界 500 强、中国 500 强、民营 100 强、制造业 100 强或示范带动力强的企业在区内设立的区域总部、研发中心和销售(结算)中心,按兰州高新区财政实得税收前三年60%、后两年 40% 的比例给予奖励。对引进并认定为企业总部的楼宇业主,根据新进企业当年税收高新区财政实得部分,按照每 100 万元对应 1 万元的标准给予奖励。

For those world's top 500, China's top 500, private 100 enterprises, top-100 manufacturing enterprises or those enterprises with strong demonstration driving power that established regional headquarters, R&D center and sales (settlement) center, the reward will be given that 60% of tax reduction in former three years and 40% tax reduction in the latter two years in Lanzhou National Hi-tech Industrial Development Zone, For the building owners which have been introduced and identified as the enterprise headquarters, the reward will be given in proportion of 1/100 of financial taxes of Hitech Industrial Development Zone in that year.

第七条 Article VII

对具有引领和带动作用的 招商引资项目,在区内设立甘

肃总部或西北总部,根据贡献 给予不超过三年的房租减免优惠。对生命健康、智能制造、 新材料、大数据应用及节能环保领域项目,根据贡献给予前 三年免租后两年房租减半优惠。

As for the investment promotion projects with guiding and driving role, if Gansu Headquarters or Southwest Headquarters have been set up within the region, no more than three years' rent will be exempted based on the contributions. As for the projects in life health, intelligent manufacturing, new materials, big data application and energy conservation and environmental protection, the preference of three-year rent exemption and two-year rent halving based on the contributions.

第八条 Article VIII

对通过招商引资进入雁滩 园区和定连园区,符合园区规 划的生命健康、智能制造、新 材料、节能环保、大数据应用 及军民融合等领域重点支持项 目,可根据其技术含量、发展

前景及区域带动 性等条件,对过1 亿元的可重点或 目,待项目建认 经管委会予可给予会分一次 性不超过50万 元的奖励;对投资总额超过1亿元(含)的重点项目,待项目建成经管委会认定后,可给予一次性50-100万元的奖励。

As for the key projects in the fields of life health, intelligent manufacturing, new materials, energy conservation and environmental protection, big data application and military-civilian integration that entered Hongyan Park and Dinglian Park by investment promotion in line with the park planning, a one-time award of not more than RMB 500,000 may be given to the projects that the total investment amount is less than RMB 100 million as identified by the Project completion Economic Management Committee; A one-time award of RMB 500,000 - RMB 1 million may be given to the projects that the total investment amount is more than RMB 100 million (including) as identified by the Project completion Economic Management Committee.





第九条 Article IX

对通过招商引资进入兰州自创区,符合自创区产业导向及园区规划的,重点支持的具有独立法人资格,经认定的国家级、省级研发机构,可给予一次性300万元、200万元的支持奖励。

As for the independent legal-person entities entered Lanzhou Self-dependent Innovation Demonstration Area by investment promotion in line with the industry guidance and park planning, a one-time award of RMB 3 million and 2 million may be given as identified by the national and provincial R&D institutions.

第十条 Article X

对兰州自创区发展有重大促进 作用的项目,可以进行专题会议研 究,可采取"一企一策、一事一议" 的办法给予专项政策扶持。

As for the projects with significant promotion effect on the development of Lanzhou Self-dependent Innovation

Demonstration Area, the special policy support may be given with the method of "one enterprise, one policy; one project one discussion" by the special meeting research.

第十一条 Article XI

房地产项目不享受上述优惠政 策。

Real estate projects do not enjoy the above preferential policies.

第十二条 Article XII

本政策自2018年10月起实施, 试行期2年,由兰州高新区管委会 负责解释。

The policy shall be implemented as of the printing date for 2 years and shall be governed by Lanzhou National Hitech Industrial Development Zone Commission.

兰州高新区关于加快生物医药产业发展的若干措施



为加快兰州高新区生物医药产业高质量发展,聚力培育生物、医药主导产业,特制定本措施。

These measures are specially formulated to accelerate the high-quality development of the biomedical industry in Lazhou National Hi-tech Industrial Development Zone and to foster the leading industries of biology and medicine.

第一章 总则 Chapter 1 General items

第一条 依托现有发展基础和甘肃生物、医药资源优势,以中药与天然药物、化学药品、生物制品、医疗器械及肿瘤诊疗等为重点发展方向,以强龙头、补链条、聚集群为基本途径,以建基地、培骨干、创品牌、调机制为着力点,吸引和集聚相关产业,构筑多层次的生命科学创新发展体系,推

动生物、医药产业特色化、规模化、 集群化发展,形成产业跨越发展 新格局。

Article 1 Relying on the existing development foundation and the advantages of Gansu's biological and medical resources, focusing on the key development direction of traditional Chinese medicine and natural medicines, chemical drugs, biological products, medical devices and tumor diagnosis and treatment, etc. with strengthening leading industry, supplementing complementary chains, and accumulating advantageous clusters as the basic ways, besides, with paying attention to building bases, training backbones, creating brands, and adjusting mechanisms to attract and gather related industries. therefore, build a multi-level life science innovation and development system, and promote the development of biology and medicine industry with characteristics, scale, and clusters, and form the new pattern of development of industries Leapfrogging.

第二条 适用范围 本措施 适用于在兰州高新区区内注册 登记和纳税,具备独立法人资 格,从事生物、医药研发、生 产和服务的企事业单位。

Article 2 Scope of application These measures are applicable to enterprises and institutions which engaged in biology and medicine R & D, production and services with registration and tax payment in Lazhou National Hi-tech Industrial

Development Zone, who have independent legal personality.



第三条 发展目标 到 2025 年,以中药与天然药物、化学 药品、生物制品、医疗器械及 肿瘤诊疗等为主导的生物医药 产业整体实力明显提升,产业 结构和产品结构不断优化,创 新能力不断增强,产业的特色 化、规模化、集群化水平进一 步提高,成为我国西部地区重 要的生物、医药产业发展基地。

Article 3 development goal By 2025, the overall strength of the biopharmaceutical industry led by traditional Chinese medicine and natural medicine, chemical drugs, biological products, medical devices and tumor diagnosis and treatment has been significantly improved, the industrial structure and product structure have been continuously optimized, and the innovation ability has been continuously enhanced, The level of

industrialization, scale and clustering of the industry has been further improved and it has become an important development base for the biopharmaceutical industry in the western region of China.

1. 产业发展目标。全区生物、医药产业工业总产值力争达到 200 亿元。

1.Industry development goal. The total industrial output value of the biomedical industry in the zone strives to reach 20 billion yuan.

2. 企业发展目标。形成年主营业务收入超过50亿元的生物医药龙头企业1-2家,年主营业务收入在10亿元至50亿元之间的生物医药企业5-8家。力争建成1-2个工业产值超100亿元的生物、医药产业集聚区。

2. Enterprise development goals. 1-2 leading biopharmaceutical companies with an annual main business income of more than 5 billion yuan will be formed, and 5-8 biomedical companies with an annual main business income of from 1 billion yuan to 5 billion yuan will be formed, Striving to build 1-2 biomedical industry clusters with an industrial output value exceeding 10 billion yuan.

3. 重点品种发展目标。形

成 2-3 个年销售额过 10 亿元的重磅品种, 4-6 个年销售额在 5 亿元至 10 亿元之间的拳头品种, 15 个年销售额过 1 亿元的优势品种。推动品种结构优化升级,使重点医药品种在所处类别药物中市场占有率为全国前三。

3.Development goals of key varieties. 2-3 heavy varieties with annual sales exceeding 1 billion yuan will be formed. 4-6 fist varieties with annual sales between 500 million and 1 billion yuan will be formed, and 15 superior varieties with annual sales exceeding 100 million yuan will be formed. Promote the optimization and upgrading of the variety structure, so that the market share of key pharmaceutical varieties in the category of drugs ranks the top three in the whole country.

4. 技术创新发展目标。力争仿制药、生物制品 2-3 个,创新药开发 4-6 个,研发上市二类、三类医疗器械新产品 30 个。

4.Technology innovation development goals. Strive for forming 2-3 generic medicines and biological products, 4-6 innovative drug development, and 30 new products of listed Class II and Class III medical devices.

5. 人才引进目标。力争引进生物医药类高层次人才 100 名。

5.Talent introduction goal. Strive to introduce 100 high-level talents in the field of biomedicine.





第二章 主要任务 Chapter Two Main Tasks

第四条 鼓励医美产业园、 兰州生物、陇神戎发、中牧股份、 中农威特、西脉医疗等龙头企业 开展自主创新、技术引进和国际 合作,实施跨地区、跨所有制收 购兼并重组,提高产业集中度, 推动产业结构调整和转型升级。 支持区内龙头企业整合资积, 鼓励医药和化工、医疗器械和 装备、原材料和制剂企业强强 联合,形成上下游一体化的企 业集团。加快推进生物医药相 关生产装备、原材料供应、物流、 销售和服务外包等上下游产业 链企业同步发展。

Article 4 Leading enterprises such as Yimei Industrial Park, Lanzhou Biology, Longshen Rongfa, Zhongmu, Zhongnong Witt, Ximai Medicine and other leading enterprises are encouraged to carry out independent innovation, technology introduction and

international cooperation, implement cross-regional and cross-all acquisitions and restructure, increase industrial concentration and promote industrial restructuring, transformation and upgrading. Support the leading enterprises in the region to integrate resources, and encourage companies of pharmaceutical and chemical, medical device and equipment, raw material and pharmaceutical to join forces to form an integrated upstream and downstream enterprise group. Accelerate the simultaneous development of upstream and downstream industry chain enterprises such as biomedicine-related production equipment, raw material supply, logistics, sales and service outsourcing.



第五条 加快定连园区生物医药产业基地建设,完善产业载体和基础设施配套,引导生物、医药企业向产业基地聚集,有效发挥区域产业和技术优势,打造产业化集群。围绕龙头企业,配套发展一批技术精、质量高的医药中间体、辅料、包材等中小企业,形成大中小企业分工协作、互利共赢的产业结构。支持高新区生物、医药产业基金、久有股权投资基金管理有限公司等与区外投资引导基金合作,以股权投资等方式引导生物医药产业项目落户园区。

Article 5 Accelerate the construction of the biological and pharmaceutical industry bases in Dinglian Park, improve the industrial carriers and infrastructure facilities, guide bio-pharmaceutical enterprises to gather in the industrial bases, effectively exert regional industrial and technological advantages, and create industrial clusters. Around the leading enterprises, a group of small and medium-sized enterprises such as pharmaceutical intermediates, auxiliary materials, and packaging materials with sophisticated technology and high quality will be developed to form an industrial structure of harmonious division and orderly cooperation for large and small enterprises with mutual benefit. Support biologypharmaceutical industry funds, Jiuyou equity investment fund management Co., Ltd. and other funds to guide biomedical industry projects to settle in the park through cross-zone equity investment.

第六条 建立政产学研用相结合的创新服务平台体系,推进甘肃药物产业研究院、肽谷研究院、中药现代制药工程研究院等新型研发机构建设,实现资源共享与互联互通。搭建交流服务平台,促进药品、保健食品批准文号供求见面,推动药品品种、保健食品资源有序合理流动,促进企业产品结构优化。

Article 6 Establish an innovative service platform system combining government, industry, academy, research and usage, promote the construction of new R & D institutions such as Gansu Pharmaceutical Industry Research Institute, Peptide Valley Research Institute, Chinese Medicine Modern Pharmaceutical Engineering Research Institute, and achieve resource sharing and interconnection. Build an exchange service platform, promote the meeting of supply and demand of approval numbers for medicines and health foods, promote the orderly and rational flow of medicine varieties and health food resources, and promote the optimization of enterprise product structure.



_**第三章 政策措施** Chapter III Policy Measures



第七条产业落地对新投资的生物、医药研发、生产以及医疗大数据、互联网医疗等证目,固定资产(不含土地)实际投资5000万元(含)以上的,竣工验收后按照实际投资的10%给予一次性奖励,单个项目奖励最高可达1000万元。新引进的创新药、首仿药项目经认定后可以代建厂房及必的配套措施。

Article 7 Industry settlement When the industry is implemented, for newlyinvested biomedicine research and development, production, medical big data, Internet medical treatment and other projects, the actual investment of fixed assets (excluding land) is more than 50 million yuan (inclusive). After completion, according to actual investment, a onetime reward is given at 10% of actual investment, and the reward for a single project can be up to 10 million yuan. Newly-introduced innovative medicines and first generic medicines can be used to build factories and necessary supporting measures after being identified.

第八条 企业总部 对世界500强、中国500强、民营100强或境内外上市生物、医

药企业在我区设立地区总部且持续经营3年以上,且在我区统计核算的产值规模不低于10亿元的,前3年按照公司缴纳所得税高新区实得部分50%奖励;其中在区内设立具有独立法人资格研发中心的,按照该研发中心上年度核准研发费用的20%予以额外资助,最高可达1000万元。

Article 8 corporate headquarters The world's top 500, China's top 500, private 100 or domestic and overseas listed biological and pharmaceutical enterprises have established a regional headquarter in our zone and have continued to operate for more than 3 years, besides, the scale of the statistically calculated output value in our zone is not less than 1 billion yuan, the company will get 50% of the rewards, which comes from the tax paid for Lazhou National Hi-tech Industrial Development Zone in the first three years; if an R & D center with independent legal unit is established in the zone, 20% of the R & D expenses approved by the R & D center in the previous year will be used for additional funding. Up to 10 million yuan.

第九条 研发创新 对在国 内开展临床试验并在区内进行 转化的新药,根据其研发进度 分阶段予以资助。

Article 9 R & D and innovation New medicines that carry out clinical trials in China and are transformed in the zone will be funded in stages according to their R & D progress.

对取得临床软件的国家I 类新药(包括中药与天然药物、 化学药品、生物制品)的企业, 按实际投入研发费用的 40% 予以资助,最高可达500万元。 完成 |、||、|| 期临床试验的, 分别最高可达800万、1200万、 2000万元给予资助,单个企 业每年资助最高可达 2000 万 元。

Enterprises with national class I new medicines (including traditional Chinese medicines and natural medicines, chemical medicines, and biological products) that have obtained clinical software will be funded at 40% of the actual R & D expenses, up to 5 million yuan. Those who have completed Phase I, II, and III clinical trials will receive funding of up to 8 million, 12 million, and 20 million yuan respectively, and a single enterprise may provide up to 20 million yuan each year.

对取得临床软件的国家 2 类化学药、2-5类生物制品、2-6 类中药及天然药物,按实际投

入研发费用的40%予以资助, 最高可达 200 万元。完成 に Ⅱ、Ⅲ期临床试验的,分别最 高可达 200 万、500 万、1000 万元给予资助,单个企业每年 资助最高可达 1000 万元。

Enterprises with National Class 2 chemical medicines, Class 2-5 biological products, Class 2-6 traditional Chinese medicines and natural medicines that have obtained clinical software will be funded at 40% of the actual R & D expenses, up to 2 million yuan. Those who have completed Phase I. II. and III clinical trials will receive funding of up to 2 million, 5 million, and 10 million yuan respectively, and a single enterprise will provide up to 10 million yuan each year.

对取得药品批准文号的非 首个通过一致性评价的仿制药 (中药及天然药物、化学药物、 生物制品),按实际投入研发 费用的20%予以资助,最高 可达 300 万元; 单个企业每年 资助最高可达500万元。

For non-first generic drugs (traditional Chinese medicine and natural drugs, chemical drugs, biological products) that have obtained the approval number of the drug, they will be funded at 20% of the actual R & D expenditure, up to 3 million yuan; The annual funding can be up to 5 million yuan for a single enterprise.



第十条 中医药 支持中医 药科研成果转化,新获得国家 或省级中医科研课题资助的, 按上级资助的30%给予一次 性奖补。中医药领域新获得国 家发明专利的,给予发明人5 万元一次性奖励。

Article 10 Traditional Chinese medicine support the transformation of scientific research achievements of traditional Chinese medicine, and newly obtained national or provincial research grants for traditional Chinese medicine research projects shall be given a one-time award supplement at 30% of the funding provided by the higher authorities. In the field of traditional Chinese medicine, if a national invention patent is newly obtained, the inventor shall be given a one-time reward of 50,000 yuan.

第十一条 医疗器械 对新 取得三类创新型医疗器械或 甲、乙类大型医用设备已注册 证书的企业,单个产品给予 50万元一次性奖励;对取得

其他三类、二类医疗器械产品 首次注册证书的企业,单个产 品给予20万元、5万元一次 性奖励。当年每个企业累计奖 励最高可达 100 万元。

Article 11 Medical Devices For enterprises that have newly obtained Class III innovative medical devices or Class A and B largescale medical equipment registered certificates, a single product of that enterprise will be given a one-time reward of RMB 500.000: For enterprises that have newly obtained the certificate for the first time for other Class III and Class II medical device products, a single product of that enterprise will be given a one-time reward of 200,000 yuan and 50,000 yuan. In that year, the cumulative reward of each enterprise can reach up to 1 million yuan.

第十二条 扩大生产 支持 有批准文号(休眠或闲置)不 具备生产条件的生物、医药企 业生产上市许可产品,经认定, 给予该产品年销售额 5% 的奖 励,最高可达10万元。

Article12 Expansion of production support Biopharmaceutical enterprises with approval number (dormant or idle) which do not have the production conditions to produce market-licensed

products.If granted, a 5% award of annual sales will be given, up to RMB 100,000.

第十三条 委托生产 支持 取得药品或医疗器械上市许可 持有人(注册人)委托区内企 业生产上市许可产品,自产品 开始生产三年内按照每个品种 实际委托生产合同执行额(以 发票为准)的5%对受托生产 企业进行奖励。单品种三年累

计奖励每家企业最 高可达100万元, 同一企业每年奖励 最高可达200万元, 三年累计奖励最高 可达 300 万元。

Article 13 Entrusted production

support holders (registrants) who have obtained marketing authorization for drugs or medical devices to entrust enterprises in the zone to produce marketinglicensed products, and within three years from the start of production of the product, 5% of the actual entrusted production contract execution amount for each variety can be rewards for the entrusted production enterprises. The accumulative reward for a single variety in three years is up to 1 million yuan per company. The annual reward for the same enterprise is up to 2 million yuan. The

accumulative reward within three years is up to 3million

第十四条 政府收购 对首 次投放市场的创新产品实行政 府采购和优先采购。对本地医 疗机构采购区内创新药、首仿 药、高值医用耗材、检验检测 试剂和医用设备等创新产品 的,给予采购金额5%的奖励, 同一年度单个医疗机构奖励总 额最高可达 300 万元。



Article 14 The head of government Innovative products that are put on the market for the first time shall implement government procurement and priority procurement. If local medical institutions purchase innovative products such as innovative drugs, first generic drugs, high-value medical consumables, inspection and testing reagents, and medical equipment, etc., a 5% purchase amount will be awarded, and the total award for a single medical institution in the same year may be up to 3 million yuan.





第十五条公共平台对新获批国家医学中心、国家级区域医疗中心、国家临床医学研究中心、国家部委重点实验室等创新平台的单位,给予500万元一次性奖励。对生物、医药产业省级以上的公共研发平台新增项目,按照新增设备(含配套软件)采购额的20%给予采购单位一次性补贴,单个项目补贴最高可达300万元。

Article 15 Public Platforms Units with innovative platforms such as newly approved national medical centers, national regional medical centers, national clinical medical research centers, and key laboratories of national ministries will be given a one-time reward of 5 million yuan. For new projects of public research and development platforms which are above the provincial level in the biopharmaceutical industry, a one-time subsidy will be given to the purchasing unit based on 20% of the purchase amount of new equipment (including supporting software). A single project subsidy may be up to 3 million yuan.

第十六条 资质认证 对新通过国家新版药物 非临床研究质量管理规范(GLP)、药物(含医疗器械)临床试验质量管理规范(GCP)、中国 合格评定国家认定委员会(CNAS)资格认证的 生物、医药企业或机构给予资助。其中,首次 取得 GLP 认证项目达到三大项、五大项的,分别给予 100 万元、200 万元奖励;取得 GCP 资格认证的,每新增一个专业学科给予 50 万元奖励;首次取得 CNAS 认证的,给予 100 万元奖励。

Article 16 Qualification certification Pharmaceutical companies or institutions shall be given financial assistance if they have newly passed the National New Edition of Drug Non-Clinical Research Quality Management Regulations (GLP), Drug (including Medical Device) Clinical Trial Quality Management Regulations (GCP), and China National Accreditation Service for Conformity Assessment (CNAS). Among them, for the first time, if obtain the GLP certification project to reach the three major items, five major items, they will be awarded 1 million yuan, 2 million yuan reward; for GCP qualification certification, each new professional subject will be awarded 500,000 yuan; for the first time, if obtain CNAS certification, they will be awarded 1 million yuan.

对新取得 FDA(美国食品药品监督局)、EMA(欧洲药品管理局)、PMDA(日本药品医疗器械局)、CE 认证等国际权威认证的药品和医疗器械企业,每个产品年出口创汇达 100 万美元以上的,给予 3% 的奖励,单个产品最高奖励 100 万元。每个企业当年累计奖励最高可达300 万元。

For newly acquired pharmaceutical and medical device companies that have obtained FDA (United States Food and Drug Administration), EMA (European Medicines Agency), PMDA (Japan Drug and Medical Device Agency), CE certification and other international authoritative certifications, if each product is exported annually for foreign exchange earning over 1million US dollars, a 3% reward will be given, and the maximum reward for a single product will be 1 million yuan. The accumulated rewards of each enterprise can be up to 3 million yuan in that year.

第十七条 技术改造 生物医药企业运用工业互联网、大数据、人工智能等技术对现有生产设施、工艺装备进行技术改造的优秀项目,经评审分类分等级,最高按照项目投资额的 20% 予以奖励,单个企业每年资助最高可达 500 万元。

Article 17 technological transformation After reviewed and categorized, if Outstanding projects which biopharmaceutical enterprises use industrial Internet, big data, artificial intelligence and other technologies to transform existing production facilities and process equipment will be awarded up to 20% of the project investment reward, a single enterprise can be funded up to 5 million yuan per year.

第十八条 人才引育 对经认定的生物医药类的高层次人才工薪收入个人所得税前三年按照年纳税额的 100% 予以奖励,后二年按照50% 予以奖励。

Article 18 Talent Cultivation After Recognition, personal tax for salary income of high-level talents in the biological and pharmaceutical categories will be rewarded at 100% of the annual tax payment in the first three years and at 50% in the following two years.

为生物医药等产业人才开辟职称评审绿色通道,符合条件的可直接授予相应职称。加强人才乐居保障,对符合条件的生物医药高层次人才给予最高可达 200 万元购房补贴,按照人才对地方的贡献,给予最高可达 100 万元贡献奖励。完善高层次人才"一站式"服务体系,为符合条件的生物医药产业人才提供人才落户、医疗保障及子女教育等优惠待遇。

Open a green channel of job title evaluation for biomedical and other industrial talents, and those who meet the conditions can be directly awarded the corresponding job title. Strengthen the guarantee of talents' living quarters, and provide subsidies of up to 2 million yuan for qualified biomedical high-level talents, and according to the contribution to the local area, a reward of up to 1 million yuan can be given. Improve the "one-stop" service system for high-level talents, and provide qualified biomedical industry talents with preferential treatment such as talent settlement, medical security, and child education.



第十九条 金融支持 积极 鼓励各类在兰金融机构加大对 兰州高新区生物医药企业或项 目的投资力度。支持优质生物、 医药企业充分利用境内外多层 次资本市场上市挂牌融资,拓 宽直接融资渠道。对在资本市 场实现 IPO 的生物医药类企 业,按规定给予每家最高可达 500 万元奖励。

Article 19 Financial Support Actively encourage various financial institutions in Lanzhou to increase investment in biomedical enterprises or projects in Lazhou National Hi-tech Industrial Development Zone. Support highquality biopharmaceutical companies to make full use of multi-level capital markets to carry out listed financing in domestic and overseas area, besides to expand direct financing channels. For biopharmaceutical enterprises that have achieved IPO in the capital market, each company will be rewarded up to 5 million

yuan in accordance with regulations.

设立生物医药产业发展投资基金,发挥财政资金引导作用,引进社会资本,以市场化方式参股或设立涵盖项目落地、股权投资、新药引进和海外医疗服务等领域的大健康产业基金,打造生物医药和医疗健康产业基金群,投资并促成相关创新项目落户兰州高新区。

Establish a biomedical industry development investment fund, play a guiding role of financial funds, introduce social capital, participate to fund in a market-oriented way or establish a large health industry fund covering project implementation, equity investment, new drug introduction and overseas medical services, as well as create biomedicine and medical-health industry fund group, invest and promote related innovation projects to settle in Lazhou National Hitech Industrial Development

7one

加大对初创生物、医药企业的支持力度,重点支持新药、创新医疗器械项目及生物医疗产业园区建设,对区内获得股权投资的种子期项目或初创期企业,按照投资机构实际投资额的10%给予补贴,单笔补贴最高可达50万元,单家投资机构每年补贴总额可达200万元。

Increasedly support start-up biomedical enterprises, focusing on supporting new medicines, innovative medical device projects and the construction of biomedical industrial parks. For seedphase projects or startup enterprises that receive equity investment in the zone, 10% of the actual investment amount of the investment institution is granted, with a single subsidy of up to 500,000 yuan, and a single investment agency's total subsidy of up to 2 million yuan per year.

第四章 附则 Chapter IV Supplementary Provisions

第二十条 本措施自 2020 年 5 月起实施,试用期二年,由兰州高新区管委会负责解释。

Article 20 These measures will be implemented from May 2020. The time of trial is two years, and Lanzhou National Hi-tech Industrial Development Zone is responsible for explanation.

投资严要素



甘肃省电网销售电价表

Electricity Prices Table of State Grid Gansu Electric Power Company

			到户电价 Household electricity price				
		电压等级 Voltage class	电度电价 Electrical degree electricity price			基本电价 basic price	
	用电分类 Power consumption classification		Voltage	平段 Flat	低谷	最大需量 Maximum demand	变压器容量 Transformer capacity
					Trough	元 / 千瓦月 RMB/KW per month	元 / 千伏安• 月 RMB/KWA per month
	居民生活用电 Residents' living electricity	不满 1 千 伏 < 1 KV	0.7590	0.5100	0.2610		
		1千伏及 以上 ≥1KV	0.7440	0.5000	0.2560		

一般工商业及用电 General industry and commerce and electricity	不满 1 千 伏 <1 KV	0.8950	0.6043	0.3136		
	1-10 千 伏 1-10 KV	0.8800	0.5943	0.3086		
	35 千伏 以上 > 35 KV	0.8650	0.5843	0.3036		
大工业用电 Large-scale industry electricity	1-10 千 伏 1-10 KV	0.6538	0.4442	0.2345	28.5	19.0
	35 千伏 35 KV	0.6388	0.4342	0.2295	28.5	19.0
	110 千伏 110 KV	0.6238	0.4242	0.2245	28.5	19.0
	220 千伏 220KV	0.6103	0.4152	0.2200	28.5	19.0
电炉铁合金、电石、电解烧碱、电解铝生产用电 lectric Furnace iron alloy, calcium carbide, electrolytic caustic soda Electrolytic aluminum production power consuming	1-10 千 伏 1-10 KV	0.5951	0.4050	0.2149	28.5	19.0
	35 千伏 35 KV	0.5801	0.3950	0.2099	28.5	19.0
	110 千伏 110 KV	0.5666	0.3860	0.2054	28.5	19.0
	220 千伏 220KV	0.5591	0.3810	0.2029	28.5	19.0

		不满 1 千 伏 < 1 KV	0.6714	0.4489	0.2265	
		1-10 千 伏 1-10 KV	0.6564	0.4389	0.2215	
		35 千伏 及以上 ≥ 35 KV	0.6414	0.4289	0.2165	
		不满 1 千 伏 < 1 KV		0.2325		
其中 among which,	农业生产用电 Agricultural production electricity	1-10 千 伏 1-10 KV		0.2275		
		35 千伏 35 KV		0.2225		
	地下水提灌 Irrigation by lifting underground water to a higher level with a water pump, etc.	101 米及 以上 ≥ 101m		0.1905		
	地表水提灌 Irrigation by lifting surface water to a higher level with a water pump, etc.	101-200 米 101- 200m		0.1205		
		201-300 米 201- 300m		0.1105		
		300 米以 上 > 300m		0.0905		

※ 以政府行政管理部门公布的价格为准 ※ $\ensuremath{\mathbb{X}}$ The price published by administrative department $\ensuremath{\mathbb{X}}$ % of the government shall prevail%



兰州市天然气价格

The Natural Gas Prices of Lanzhou City

单位:元/M³ Unit:RMB/M³

用气类型 Gas type	用气价格(元 /M³) Gas price (RMB/M³)	备注 Notes	文号 Document No.
集中采暖用气 Central heating gas	1.80		兰发改电〔2020〕 15号 L.F.G.D. (2020) No. 15
汽车加气站用气 Gas for vehicle gas filling station	2.04/2.79 压缩气 Compressed gas of 2.04/2.79	上游供气企业供车用压缩 天然气 (CNG) 加气站用气 Compressed natural gas (CNG) for vehicles of upstream gas supply enterprises and gas at the natural gas stations	市场调节 Market regulation
工商业用气 Gas for industry and commerce	1.90	工商业用气 Gas for industry and commerce	兰发改电〔2020〕 15号 L.F.G.D. (2020) No. 15
学校、幼儿、养老院等用 气 Gas for school, kinder- garten and old people's home	1.87 管道气 Pipeline gas of 1.87	不执行阶梯价格制度、用 气价格按居民用气第一档、 第二档平均价格执行。 If no tiered pricing system is executed, gas price shall be subject to an average price of Grade I and Grade II of gas for residents.	兰发改电 〔2019 〕 298 号 L.F.G.D. (2019) No. 298
居民用气 Residential gas consumption	1.69	居民生活用气、居民壁挂 炉用气现执行阶梯价制度。 Tiered pricing system is adopted for gas for residents' life and residents' wall-hanging stove.	兰发改电 〔2019 〕 298 号 L.F.G.D. (2019) No. 298

※ 以政府行政管理部门公布的价格为准 ※※ The price published by administrative department※ of the government shall prevail※



兰州市居民阶梯气量及阶梯价格表

Table for Stepped Gas Flow and Tiered Pricing of Residents in Lanzhou

		居民生活用户 Residents'living			居民壁挂炉采暖用户 Residents'wall-hanging stove heating						
项目 Item	单位 Unit					气量	价 格 Price		气量	价 格 Price	
		Gas consumption	管道气 Pipeline gas	压缩气 Com- pressed gas	Gas consump- tion	管道气 Pipeline gas	压缩气 Com- pressed gas				
第一档 First level	M³/年 M³/year	360	1.69	3.80	2400	1.69	3.80				
第二档 Second level	M³/ 年 M³/year	361-480	2.03	4.56	2401-3000	2.03	4.56				
第三档 Third level	M³/ 年 M³/year	480 以上 More than 480	2.54	5.70	3000以上 More than 3,000	2.54	5.70				

备注:居民用户超过 4 人的经核实确认后,每增加 1 人,居民生活用气各档用气量相应增加 $72 \, \mathrm{m}^3/$ 年。 残疾人贫困户家庭用气每年赠送 96 立方米家庭生活用气(超过标准的,按 96 立方米减免,低于标准的,按实际使用量减免)。

Remarks: After the verification and confirmation of more than 4 resident users in one family, for each additional user, each level of the the residents' gas consumption will increase by 72m³/ year. 96m³ gas for family life is gifted to poor family with the disabled every year (in case of exceeding the standard, deduction shall be conducted as per 96m³; in case of being lower than the standard, deduction shall be conducted as per actual usage amount).

※ 以政府行政管理部门公布的价格为准 ※

※ The price published by administrative department ※

※ of the government shall prevail ※



兰州市用水及水蒸气价格

Water and Vapour Price in Lanzhou

用水分类 Water consump tion classifica tion		备注 Notes	文号 Document No.
非居民用水 Non-residentia water consump tion) 69		兰政办发 〔 2015 〕 289 号 L.Z.B.F. (2015) No. 289
特种用水 Specially-used water	d 15.95		兰政办发 〔 2015 〕 289 号 L.Z.B.F. (2015) No. 289
工业一次用水 Industrial prim ry water			兰政办发 〔2015 〕289 号 L.Z.B.F. (2015) No. 289
工业二次用水 Industrial sec- ondary water	- 1.30		兰政办发 〔 2015 〕 289 号 L.Z.B.F. (2015) No. 289
水蒸气 Vapor	230(元 / 吨) 230 (RMB/TON)	参照天然气锅炉运行成本 Refer to operating cost of natural gas boiler	

※ 以政府行政管理部门公布的价格为准 ※
※ The price published by administrative department
※ of the government shall prevail※